by Tamy Portillo Rodriguez | Nov 1, 2017 | Perlara science |
Perlara’s high throughput screen progress in Mucolipidosis IV (MLIV) flies… In this blog post, I’ll tell you about Perlara’s high throughput screen progress in MLIV flies. Last year, Tom Hartl reviewed some details of MLIV disease biology and described how...
by Ethan Perlstein | Sep 21, 2017 | Niemann-Pick Type A |
By Taryn Sumabat This summer at Perlara, we ramped up our efforts to develop a Drosophila model of Niemann-Pick Type A (NPA). NPA is a rare lysosomal storage disease caused by mutations in the gene Smpd1, which encodes an enzyme called acid sphingomyelinase (ASM)....
by Feba Sam | Feb 1, 2017 | Perlara science |
I, along with Nina, performed our first high-throughput screen – well really medium-throughput but high-throughput for us – on Niemann-Pick Type C (NPC) patient-derived fibroblasts a couple of months back. We wanted to do a pilot screen with the Microsource bioactives...
by Nina DiPrimio | Jan 12, 2017 | Perlara science |
Well it has been a little while since I wrote a post, and a lot has happened since then, which I am sure you read about in our blogs and tweets. We changed our company name, partnered with Novartis and started partnering with patient groups to engineer our organisms...
by Tom Hartl | Jul 1, 2016 | Science |
Last week I attended the 2016 Mucolipidosis Type IV (MLIV) conference in Atlanta. It was organized and hosted by the MLIV Foundation. The attendees were about 50/50 MLIV scientists and MLIV families/patients. This is a small and very tight knit community. The MLIV...
